Premium
The Economics of Drug Discovery and the Ultimate Valuation of Pharmacotherapies in the Marketplace
Author(s) -
Sollano JA,
Kirsch JM,
Bala MV,
Chambers MG,
Harpole LH
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.117
Subject(s) - clinical pharmacology , valuation (finance) , reimbursement , business , drug discovery , health economics , drug development , actuarial science , drug , pharmacology , economics , medicine , health care , finance , bioinformatics , economic growth , biology
Although it is commonly believed that the innovation of new medicines is of paramount importance for improving the health and quality of life of patients, there is also a keen recognition regarding upward‐spiraling costs of innovation, drug discovery, and drug development against a backdrop of dwindling successes in research and development (R&D) efforts. We propose a new model of valuation of pharmacotherapies that attempts to secure an adequate return on investment in innovation by ensuring optimal pricing and reimbursement. Clinical Pharmacology & Therapeutics (2008); 84 , 2, 263–266 doi: 10.1038/clpt.2008.117